IL290035A - History of pyridine as tmem16a modulators for use in the treatment of respiratory conditions - Google Patents

History of pyridine as tmem16a modulators for use in the treatment of respiratory conditions

Info

Publication number
IL290035A
IL290035A IL290035A IL29003522A IL290035A IL 290035 A IL290035 A IL 290035A IL 290035 A IL290035 A IL 290035A IL 29003522 A IL29003522 A IL 29003522A IL 290035 A IL290035 A IL 290035A
Authority
IL
Israel
Prior art keywords
tmem16a
modulators
treatment
pyridine derivatives
respiratory conditions
Prior art date
Application number
IL290035A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tmem16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1910607.9A external-priority patent/GB201910607D0/en
Priority claimed from GBGB2005739.4A external-priority patent/GB202005739D0/en
Application filed by Tmem16A Ltd filed Critical Tmem16A Ltd
Publication of IL290035A publication Critical patent/IL290035A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL290035A 2019-07-24 2022-01-23 History of pyridine as tmem16a modulators for use in the treatment of respiratory conditions IL290035A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1910607.9A GB201910607D0 (en) 2019-07-24 2019-07-24 Compounds
GBGB2005739.4A GB202005739D0 (en) 2020-04-20 2020-04-20 Compounds
PCT/GB2020/051778 WO2021014166A1 (en) 2019-07-24 2020-07-24 Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions

Publications (1)

Publication Number Publication Date
IL290035A true IL290035A (en) 2022-03-01

Family

ID=71948615

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290035A IL290035A (en) 2019-07-24 2022-01-23 History of pyridine as tmem16a modulators for use in the treatment of respiratory conditions

Country Status (16)

Country Link
US (1) US20220235006A1 (cg-RX-API-DMAC10.html)
EP (1) EP4003516A1 (cg-RX-API-DMAC10.html)
JP (1) JP7583022B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220063162A (cg-RX-API-DMAC10.html)
CN (1) CN114616226B (cg-RX-API-DMAC10.html)
AU (1) AU2020317036A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022001164A2 (cg-RX-API-DMAC10.html)
CA (1) CA3145120A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000147A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022002022A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220072A (cg-RX-API-DMAC10.html)
IL (1) IL290035A (cg-RX-API-DMAC10.html)
MX (1) MX2022000841A (cg-RX-API-DMAC10.html)
PE (1) PE20221441A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022550181A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021014166A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003516A1 (en) * 2019-07-24 2022-06-01 Tmem16A Limited Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
KR20260025059A (ko) * 2024-08-13 2026-02-23 전남대학교산학협력단 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042524A1 (en) 2003-10-30 2005-05-12 Virochem Pharma Inc. Pyridine carboxamide and methods for inhibiting hiv integrase
EP3612180B1 (en) 2017-04-17 2023-10-11 The Regents of the University of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
EP4003516A1 (en) * 2019-07-24 2022-06-01 Tmem16A Limited Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions

Also Published As

Publication number Publication date
CN114616226A (zh) 2022-06-10
BR112022001164A2 (pt) 2022-03-15
WO2021014166A1 (en) 2021-01-28
US20220235006A1 (en) 2022-07-28
JP2022541311A (ja) 2022-09-22
AU2020317036A1 (en) 2022-03-17
KR20220063162A (ko) 2022-05-17
CO2022002022A2 (es) 2022-06-10
PE20221441A1 (es) 2022-09-21
CN114616226B (zh) 2025-03-04
MX2022000841A (es) 2022-06-08
CA3145120A1 (en) 2021-01-28
CR20220072A (es) 2022-06-29
PH12022550181A1 (en) 2023-01-16
EP4003516A1 (en) 2022-06-01
JP7583022B2 (ja) 2024-11-13
CL2022000147A1 (es) 2022-10-07

Similar Documents

Publication Publication Date Title
PL3675854T3 (pl) Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3
IL265215B (en) Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
PL3618829T3 (pl) Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem
PL3634417T3 (pl) Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL271117B (en) Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
EP3191100A4 (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL256684B (en) Medicinal compounds and preparations for the treatment of social disorders and substance use disorders
IL272121A (en) Preparation and methods for the treatment of myopia
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
SI3452465T1 (sl) Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
EP3738559B8 (de) System zur augentherapie mittels gewebebearbeitung durch nichtlineare wechselwirkung
PL3283064T3 (pl) Pochodne do zastosowania w atrofii mięśni
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
LT4048229T (lt) Farmacinė kompozicija, skirta panaudoti įvairių etiologijų cistito gydymui
EP3371154A4 (en) Heterocyclic derivatives and their use in the treatment of central nervous system disorders
IL275247A (en) History of glucosamine for the prevention or treatment of joint disorders
EP3507277B8 (en) Hydroxynorketamine derivatives for the treatment of disorders
IL286533A (en) Compounds for use in the treatment of adcy5-related dyskinesia
HK40074743A (en) Methylthioninium for use in the treatment of synaptopathies
HK40044464A (en) R-fadrozole for use in the treatment of aldostonerism
GB201901130D0 (en) Formulation for the treatment of tendinopathies
HK40031097A (en) Composition and methods for the treatment of myopia